|
Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 18S ( Supplement), :
© 2009 American Society of Clinical Oncology
OS Results for Non-Inferiority (2 2 comparisons) and Individual Regimens
| 2 x 2 comparisons Per Protocol |
1 year OS (95% CI) |
Median OS |
HR (95% CI) |
|
| 5FU: ECF + EOF |
39.4%(35.0–43.7) |
9.6mths |
1 |
| Capecitabine: ECX + EOX |
44.6%(40.1–49.0) |
10.9mths |
0.86(0.75–0.99)* |
| Cisplatin: ECF + ECX |
40.1%(35.7–44.4) |
10.1mths |
1 |
| Oxaliplatin: EOX + EOF |
43.9%(39.4–48.4) |
10.4mths |
0.92(0.80–1.05)* |
| Regimens ITT |
|
|
|
| ECF n = 263 |
37.7%(31.8–43.6) |
9.9mths |
1 |
| EOF n = 245 |
40.4%(34.2–46.5) |
9.3mths |
0.95(0.79–1.15) |
| ECX n = 250 |
40.8%(34.7–46.9) |
9.9mths |
0.92(0.76–1.11) |
| EOX n = 244 |
46.8%(40.4–52.9) |
11.2mths |
0.80(0.65–0.97) |
|
* The Upper limit of the 95% CI excludes 1.23 we can therefore conclude non-inferiority;
p = 0.025 comparison with ECF.
|
